Treatment options for urticaria
Pro Research Analysisby 
Searched over 200M research papers
First-Line Treatment Options for Urticaria: Antihistamines
Second-generation H1-antihistamines are the first-line treatment for both acute and chronic urticaria due to their safety and effectiveness. If standard doses are not effective, the dose can be increased up to four times the usual amount to achieve better symptom control Hidvégi2021Asero2013Asero2024+3 MORE.
Second-Line and Adjunctive Therapies: Omalizumab and Beyond
For patients who do not respond to high-dose antihistamines, omalizumab, a monoclonal anti-IgE antibody, is the recommended next step and has shown strong efficacy and safety in chronic spontaneous urticaria (CSU) Kolkhir2019Asero2024Zuberbier2024+2 MORE. Omalizumab is also being explored for use in children and at higher doses for difficult cases Kolkhir2019Wedi2021.
Other adjunctive options include H2-antihistamines, leukotriene receptor antagonists (such as montelukast), and short courses of corticosteroids for acute flares, though these are generally considered supportive rather than primary treatments Asero2013Schaefer2017Antia2018+1 MORE.
Third-Line and Alternative Treatments: Immunosuppressants and Nonbiologics
If symptoms persist despite antihistamines and omalizumab, immunosuppressive agents like cyclosporine or azathioprine may be considered, especially in refractory cases Hidvégi2021Asero2013Asero2024+3 MORE. Other nonbiologic options with some evidence of benefit include dapsone, hydroxychloroquine, methotrexate, sulfasalazine, mycophenolate mofetil, intravenous immunoglobulin (IVIG), and ultraviolet light therapy Asero2013Staubach2024Holm2018. These treatments are generally reserved for severe, treatment-resistant cases due to potential side effects and limited supporting evidence Asero2013Holm2018.
Emerging and Future Therapies: Biologics and Targeted Agents
Several new therapies are under investigation for chronic urticaria, especially for patients who do not respond to current options. These include:
- New anti-IgE monoclonal antibodies such as ligelizumab and UB-221, which have shown promise in clinical trials and may be more effective for some patients than omalizumab Kolkhir2019Zuberbier2024Wedi2021.
- Biologics targeting other immune pathways, such as dupilumab (targeting IL-4 and IL-13), reslizumab, mepolizumab, and benralizumab Kolkhir2019Asero2024Zuberbier2024.
- Bruton’s tyrosine kinase (BTK) inhibitors (e.g., remibrutinib, fenebrutinib), spleen tyrosine kinase inhibitors, and drugs targeting the Mas-related G-protein–coupled receptor X2 (MRGPRX2) Kolkhir2019Asero2024Zuberbier2024.
- Other novel targets include Siglec-8, C5a and its receptor, and cytokines like interleukin 33, interleukin 25, and thymic stromal lymphopoietin Kolkhir2019Asero2024Zuberbier2024.
Special Considerations: Comorbidities and Personalized Approaches
Treatment strategies can be safely combined in patients with comorbidities, and a personalized, endotype-based approach is emerging to better match therapies to individual disease mechanisms Staubach2024Zuberbier2024. This is especially important as some patients do not respond to the standard stepwise approach due to underlying differences in disease drivers .
Conclusion
The mainstay of urticaria treatment remains second-generation antihistamines, with omalizumab as the next step for resistant cases. For those who do not respond, immunosuppressants and nonbiologic agents may be considered, though evidence is limited. Exciting new therapies targeting specific immune pathways are in development and may offer hope for patients with difficult-to-treat urticaria. Personalized treatment approaches are likely to improve outcomes as our understanding of the disease advances Kolkhir2019Hidvégi2021Asero2013+7 MORE.
Sources and full results
Most relevant research papers on this topic
New treatments for chronic urticaria.
New treatments for chronic urticaria, including off-label use of existing drugs and novel therapies in clinical trials, show promise in improving patient outcomes.
DOI